相关临床试验
12
3 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
25.0%
已完成
3
25.0%
招募中
4
33.3%
终止
2
16.7%
暂无批准数据
- Xoma Royalty has agreed to acquire Generation Bio, a struggling gene therapy developer, for approximately $4.29 per share in its latest "zombie biotech" acquisition. - Generation Bio raised $200 million in its 2020 IPO to develop lipid nanoparticle-based gene therapy technology but faced setbacks including disappointing preclinical results and workforce reductions. - The acquisition includes contingent value rights for shareholders, potentially providing additional payments from cash holdings, lease savings, Moderna partnership milestones, and proceeds from delivery technology sales. - Generation Bio recently slashed 90% of its workforce and began strategic review after touting RNA delivery technology for T cells, fitting Xoma's pattern of acquiring distressed biotech companies.
- XOMA Royalty Corporation reported robust financial performance in Q3 2025, receiving $43.9 million in royalties and milestones from partners in the first nine months of 2025, including $14.3 million in Q3 royalties. - The company completed strategic acquisitions of Turnstone Biologics and HilleVax while announcing planned acquisitions of LAVA Therapeutics and Mural Oncology to expand its royalty portfolio. - Key pipeline developments include Zevra Therapeutics submitting a Marketing Authorization Application to the EMA for arimoclomol in Niemann-Pick Type C disease and Rezolute Bio expecting Phase 3 ersodetug trial results in December 2025. - XOMA Royalty achieved net income of $14.1 million in Q3 2025 compared to a net loss of $17.2 million in the same period of 2024, demonstrating improved operational performance.
- XOMA Royalty's subsidiary XRA 5 Corp. will acquire clinical-stage immuno-oncology company Mural Oncology for $2.035 per share base price, potentially reaching $36.2 million total value. - The acquisition represents a 13.1% premium over Mural's recent share price and a 97.6% premium over pre-strategic review value, maximizing shareholder returns. - This deal continues XOMA's aggressive 2025 acquisition strategy, following recent mergers with HilleVax and Turnstone Biologics to expand its late-stage biotech portfolio.
- Xoma Royalty Corp. agreed to acquire Mural Oncology for $2.035-2.240 per share, valuing the deal at $35.2-38.8 million depending on closing cash balance. - The acquisition follows Mural's discontinuation of lead IL-2 therapy nemvaleukin alfa after failed Artistry-6 and 7 trials, leading to 90% workforce reduction in April. - Xoma will wind down Mural's operations as part of a growing trend where investment firms acquire struggling biotechs trading below cash value for liquidation. - The deal represents Xoma's fourth oncology acquisition this year, following purchases of Turnstone Biologics, Lava Therapeutics, and HilleVax.
- Mural Oncology is discontinuing all clinical development of nemvaleukin alfa after the immunotherapy failed to meet target goals in melanoma and ovarian cancer trials. - The Waltham-based biotech company will lay off approximately 104 employees (90% of its workforce) by the end of the second fiscal quarter of 2025. - With approximately $144.4 million in cash reserves, Mural is now exploring strategic alternatives including potential acquisitions, mergers, or business combinations to maximize shareholder value.
- Mural Oncology's ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer has reached 75% of overall survival events. - Top-line data from ARTISTRY-6, a phase 2 trial of nemvaleukin monotherapy in mucosal melanoma, is expected in Q2 2025, potentially supporting accelerated approval. - Preliminary data for less-frequent intravenous dosing of nemvaleukin in cutaneous melanoma is anticipated in 1H and 2H 2025 for monotherapy and combination therapy, respectively. - Mural Oncology plans to submit an IND application for MURA-8518, a novel IL-18 candidate, in Q4 2025, expanding its cytokine-based immunotherapy pipeline.
- Nemvaleukin, an engineered IL-2 fusion protein, demonstrates tolerability and antitumor activity in the ARTISTRY-1 phase 1/2 trial, both as monotherapy and in combination with pembrolizumab. - The study showed a 10% overall response rate with nemvaleukin monotherapy and a 13% ORR with nemvaleukin plus pembrolizumab across heavily pretreated patients with advanced solid tumors. - Notably, a 21% ORR was observed in patients with platinum-resistant ovarian cancer (PROC), a population that typically does not respond well to immunotherapy. - Mural Oncology's ongoing registrational trials, based on ARTISTRY-1, are expected to have data readouts in late Q1/early Q2 2025 for PROC and Q2 2025 for mucosal melanoma.
- Mural Oncology remains on track with late-stage trials for nemvaleukin alfa, expecting data readouts for platinum-resistant ovarian cancer in late Q1/early Q2 2025. - Top-line results from the ARTISTRY-6 trial cohort 2, focusing on mucosal melanoma, are anticipated in Q2 2025, with a target response rate of 25%. - Candidate nominations for IL-18 and IL-12 programs are expected in Q4 2024, with an IND submission for the IL-18 program planned for Q4 2025. - The company reaffirms its cash runway guidance, projecting sufficient funds to support operations into the fourth quarter of 2025.
- Mural Oncology's ARTISTRY-7 trial, evaluating nemvaleukin plus pembrolizumab in platinum-resistant ovarian cancer, anticipates interim data in early Q2 2025. - Top-line results from the ARTISTRY-6 trial of nemvaleukin in mucosal melanoma are expected in Q2 2025, potentially supporting a BLA submission. - Mural Oncology plans to submit an Investigational New Drug (IND) application for its IL-18 program to the FDA in Q4 2025.
